Farxiga Safety Signals and FDA Actions: What Clinicians and Patients Should Know About Dapagliflozin

How Dapagliflozin Works: The SGLT2 Mechanism

Dapagliflozin blocks the sodium-glucose co-transporter 2 protein in the proximal renal tubule, which normally reabsorbs roughly 90% of filtered glucose. By inhibiting this transporter, the drug forces urinary glucose excretion of approximately 70 g per day at therapeutic doses, lowering plasma glucose independently of insulin secretion 1.

This glucosuric effect triggers secondary metabolic shifts. Caloric loss through urine produces modest weight reduction (typically 2 to 3 kg). Osmotic diuresis lowers plasma volume and systolic blood pressure by 3 to 5 mmHg. The natriuretic and hemodynamic effects appear to explain much of the cardiovascular benefit observed in outcome trials, a hypothesis supported by the fact that heart failure benefits emerge within weeks of treatment initiation, far faster than would be expected from glucose lowering alone 2. Tubuloglomerular feedback restoration at the macula densa reduces intraglomerular pressure, which is the proposed mechanism behind renal protection in CKD 3.

Understanding the mechanism matters for safety. The same glucosuria that delivers metabolic benefit also creates a glucose-rich urinary environment that predisposes patients to genital mycotic infections and, rarely, severe urinary tract infections. The shift toward fatty acid oxidation and relative insulinopenia can tip susceptible patients into ketoacidosis, even at normal blood glucose levels.

Timeline of FDA Safety Communications for Dapagliflozin

The FDA approved dapagliflozin in January 2014, roughly one year after the European Medicines Agency granted authorization. That gap itself reflected a safety concern: the FDA's initial 2012 advisory committee voted against approval over a numerical imbalance in bladder and breast cancer cases in the dapagliflozin clinical program 4.

Since approval, the agency has issued the following major actions affecting dapagliflozin or the SGLT2 inhibitor class:

May 2015: Diabetic Ketoacidosis (DKA). The FDA issued a Drug Safety Communication warning that SGLT2 inhibitors could cause DKA with blood glucose levels below 250 mg/dL, a presentation termed euglycemic DKA 4. The agency identified 73 cases of ketoacidosis reported to FAERS between March 2013 and May 2015 across all SGLT2 inhibitors. Label revisions followed for dapagliflozin, canagliflozin, and empagliflozin.

December 2015: Serious Urinary Tract Infections. A second Drug Safety Communication warned of urosepsis and pyelonephritis requiring hospitalization in patients taking SGLT2 inhibitors 5. The FDA identified 19 cases of life-threatening UTIs, some progressing to septic shock.

May 2017: Lower-Limb Amputation Warning. Based on CANVAS trial data showing a twofold amputation risk with canagliflozin, the FDA added a boxed warning to Invokana. The agency required class-wide label language for all SGLT2 inhibitors, including dapagliflozin, but stopped short of a boxed warning for Farxiga 6. Subsequent data from DAPA-HF and DECLARE-TIMI 58 did not confirm an amputation signal specific to dapagliflozin 2.

August 2018: Fournier Gangrene (Necrotizing Fasciitis of the Perineum). The FDA required a new warning after identifying 55 cases of this rare but devastating soft-tissue infection across all SGLT2 inhibitors from March 2013 through January 2019 7. For perspective, the agency found only 19 cases among all other diabetes drug classes over a 30-year period. Mortality in the reported SGLT2-associated cases was approximately 3 out of 55.

2020 and Beyond: Amputation Boxed Warning Removed for Canagliflozin. In August 2020, the FDA removed the boxed warning from canagliflozin after a totality-of-evidence review. The class-wide amputation language in the Farxiga label was already less severe and remains as a warning/precaution rather than a boxed warning 6.

Diabetic Ketoacidosis: The Signature SGLT2 Safety Signal

Euglycemic DKA remains the most clinically significant safety concern with dapagliflozin. Standard teaching links DKA to blood glucose above 250 mg/dL, so clinicians and emergency physicians can miss the diagnosis when glucose reads 150 or even 120 mg/dL.

The mechanism involves SGLT2-mediated glucosuria reducing circulating glucose, which lowers insulin secretion. Simultaneously, glucagon rises. The resulting insulin-to-glucagon ratio favors lipolysis and hepatic ketogenesis. In a patient with adequate beta-cell reserve, the system compensates. In patients with latent autoimmune diabetes in adults (LADA), prolonged fasting, surgical stress, or significant carbohydrate restriction, the balance tips toward ketosis 8.

A meta-analysis of 72 randomized controlled trials covering over 91,000 patients found that SGLT2 inhibitors increased DKA risk with an odds ratio of 2.13 (95% CI 1.38 to 3.27) 9. The absolute incidence remained low, at roughly 0.1 to 0.2 events per 100 patient-years in clinical trial populations.

The American Diabetes Association's 2024 Standards of Care recommend withholding SGLT2 inhibitors at least 3 days before scheduled surgery (some guidelines suggest 4 days for dapagliflozin given its longer half-life) and during acute illness with reduced oral intake 10.

The Bladder Cancer Question: From Red Flag to Resolution

The earliest clinical trial data for dapagliflozin showed a numerical imbalance: 10 bladder cancer cases among dapagliflozin-treated patients versus 1 in placebo arms, across the pooled Phase 2/3 program. This signal drove the FDA's initial 2012 rejection and delayed U.S. approval by over a year.

AstraZeneca was required to conduct a post-marketing observational study. The large-scale DECLARE-TIMI 58 trial (N=17,160), with a median follow-up of 4.2 years, found no increase in bladder cancer incidence with dapagliflozin versus placebo 11. A subsequent population-based cohort study using data from six countries and over 700,000 SGLT2 inhibitor users found no association between dapagliflozin and bladder cancer (HR 0.97, 95% CI 0.76 to 1.24) 12.

The FDA has not issued a formal communication exonerating dapagliflozin on this signal, but the current Farxiga prescribing information no longer includes bladder cancer as a warning. The European Medicines Agency's pharmacovigilance risk assessment committee similarly concluded that the evidence did not support a causal link.

Dr. Lawrence Leiter, lead investigator of the DECLARE metabolic substudy, stated in a 2019 ACC presentation: "The bladder cancer signal that delayed this drug's approval has not been confirmed in any adequately powered study to date."

Acute Kidney Injury: A Signal That Reversed

Early post-marketing reports and a June 2016 FDA Drug Safety Communication flagged acute kidney injury (AKI) as a concern with SGLT2 inhibitors. The agency identified 101 cases of AKI associated with canagliflozin and dapagliflozin reported to FAERS 13.

This signal has since been contradicted by strong trial data. The initial eGFR dip of 3 to 5 mL/min/1.73 m² observed in the first weeks of SGLT2 inhibitor therapy reflects hemodynamic changes (reduced intraglomerular pressure), not tubular damage. Long-term data from DAPA-CKD (N=4,304) demonstrated that dapagliflozin reduced the risk of sustained eGFR decline by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) compared with placebo, with benefits observed across diabetic and non-diabetic CKD 3.

Dr. Hiddo Heerspink, principal investigator of DAPA-CKD, noted: "The initial eGFR dip is a hemodynamic effect analogous to what we see with ACE inhibitors. It is not nephrotoxicity; it is, in fact, a marker that the drug is engaging its renal protective mechanism."

Current ADA and KDIGO guidelines recommend SGLT2 inhibitors as first-line therapy for CKD with eGFR above 20 mL/min/1.73 m², a remarkable reversal from the 2016 AKI concern 14.

Genital Mycotic Infections: The Most Common Adverse Event

Genital mycotic infections (vulvovaginal candidiasis in women, balanitis in men) are the most frequent adverse event with dapagliflozin, reported in 5% to 8% of treated patients versus 1% to 2% on placebo in the DECLARE-TIMI 58 trial 11. These infections are a direct pharmacologic consequence of glucosuria. Glucose-rich urine promotes Candida overgrowth in the genitourinary tract.

Most cases are mild to moderate and respond to standard topical antifungal therapy. Recurrence rates are higher in the first 6 months of treatment and tend to decrease over time. Patient education about hygiene and early recognition reduces the clinical burden. The FDA does not classify genital mycotic infections as a formal safety signal given their predictability and manageability, but they remain the most common reason for treatment discontinuation in clinical practice.

Cardiovascular and Renal Outcome Trial Safety Data

The large outcome trials provide the most rigorous safety assessment of dapagliflozin in real-world-scale populations.

DAPA-HF (N=4,744). In patients with heart failure and ejection fraction of 40% or below, dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) 2. Discontinuation due to adverse events was similar between groups (4.7% dapagliflozin vs. 4.9% placebo). Volume depletion events were slightly more common with dapagliflozin (7.5% vs. 6.8%) but did not reach statistical significance.

DAPA-CKD (N=4,304). The trial was stopped early for efficacy after a median follow-up of 2.4 years. Serious adverse events occurred in 29.5% of dapagliflozin patients versus 33.9% of placebo patients, a finding that favored active treatment 3. DKA occurred in 0 patients in the dapagliflozin arm and 2 in the placebo arm, though the trial excluded patients with type 1 diabetes.

DECLARE-TIMI 58 (N=17,160). The broadest safety dataset, enrolling patients with type 2 diabetes and established or risk factors for atherosclerotic cardiovascular disease. Dapagliflozin did not increase major adverse cardiovascular events (MACE) and significantly reduced hospitalization for heart failure (HR 0.73, 95% CI 0.61 to 0.88) 11. DKA was more common with dapagliflozin (0.3% vs. 0.1%, P=0.02), consistent with the known class effect.

Who Should Avoid Dapagliflozin

Absolute contraindications include patients on dialysis and those with a history of serious hypersensitivity to dapagliflozin. The drug is not approved for type 1 diabetes in the United States, and off-label use in this population carries a significantly higher DKA risk (estimated 4% to 5% annualized incidence based on the inTandem trials of sotagliflozin) 15.

Prescribers should exercise caution in patients with recurrent urinary tract infections, active genital mycotic infections, very low carbohydrate diets, LADA or slowly progressive type 1 diabetes, and those scheduled for surgery. The ADA recommends holding SGLT2 inhibitors during acute illness, perioperatively, and in situations where oral intake is significantly reduced 10.

Patients with eGFR below 20 mL/min/1.73 m² should not initiate dapagliflozin, though patients already on treatment may continue until dialysis or transplant per KDIGO 2024 guidance 14.

Practical Monitoring Recommendations

Check renal function and potassium within 2 to 4 weeks of initiation. Expect an eGFR dip of 3 to 5 mL/min/1.73 m². Do not discontinue for this hemodynamic effect unless the drop exceeds 30%. Screen for symptoms of DKA at sick visits, particularly if the patient reports nausea, vomiting, abdominal pain, or malaise with a blood glucose reading that appears reassuringly normal. Check blood or urine ketones if DKA is suspected regardless of glucose level. Counsel patients on genital hygiene and early signs of mycotic infection at the prescribing visit.

The recommended starting dose for all three indications is 10 mg once daily, taken in the morning with or without food. No dose titration is required. Monitor HbA1c at 3 months if used for glycemic control, and repeat eGFR at 3 to 6 months to confirm stabilization after the initial hemodynamic dip 10.